Morgan Stanley upgraded Qiagen to Overweight from Equal Weight with a price target of $51, up from $49.48. Shares declined about 17% in 2023, driven by mainly multiple contraction, notes the analyst, who believes the performance gap with peers should start to narrow as earnings visibility improves over the year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on QGEN:
- QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification
- Qiagen price target lowered to $60 from $61.86 at Citi
- Qiagen reports Q4 EPS 55c consensus 55c
- Qiagen rumor highlighted again in Betaville blog
- QGEN Upcoming Earnings Report: What to Expect?
